A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions

Clinical Pharmacology and Therapeutics

Volumn 93, Issue 6, 2013, Pages 564-571

  Halama, B ^a   Hohmann, N ^a   Burhenne, J ^a   Weiss, J ^a   Mikus, G ^a   Haefeli, W E ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A5; CYTOCHROME P450 INHIBITOR; KETOCONAZOLE; MIDAZOLAM;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG INHIBITION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HUMAN; HUMAN EXPERIMENT; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE;

ADOLESCENT; ADULT; ALLELES; AREA UNDER CURVE; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; GENOTYPE; HUMANS; KETOCONAZOLE; MALE; MIDAZOLAM; MIDDLE AGED; SEX CHARACTERISTICS;

EID: 84878264246     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.27     Document Type: Article

References (37)

1. Evans, W.E. & Relling, M.V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286, 487-491 (1999).
2. Backman, J.T., Kivistö, K.T., Olkkola, K.T. & Neuvonen, P.J. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur. J. Clin. Pharmacol. 54, 53-58 (1998).
3. Lee, J.I., Chaves-Gnecco, D., Amico, J.A., Kroboth, P.D., Wilson, J.W. & Frye, R.F. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. Clin. Pharmacol. Ther. 72, 718-728 (2002).
4. Katzenmaier, S., Markert, C., Riedel, K.D., Burhenne, J., Haefeli, W.E. & Mikus, G. Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using a limited sampling strategy. Clin. Pharmacol. Ther. 90, 666-673 (2011).
5. Fuhr, U., Jetter, A. & Kirchheiner, J. Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach. Clin. Pharmacol. Ther. 81, 270-283 (2007).
6. Chalasani, N., Gorski, J.C., Patel, N.H., Hall, S.D. & Galinsky, R.E. Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: efects of transjugular intrahepatic portosystemic shunts. Hepatology 34, 1103-1108 (2001).
7. Burhenne, J. et al. Quantifcation of femtomolar concentrations of the CYP3A substrate midazolam and its main metabolite 1'-hydroxymidazolam in human plasma using ultra performance liquid chromatography coupled to tandem mass spectrometry. Anal. Bioanal. Chem. 402, 2439-2450 (2012).
8. Kashuba, A.D., Bertino, J.S. Jr, Rocci, M.L. Jr, Kulawy, R.W., Beck, D.J. & Nafziger, A.N. Quantifcation of 3-month intraindividual variability and the infuence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam. Clin. Pharmacol. Ther. 64, 269-277 (1998).
9. Chainuvati, S. et al. Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail". Clin. Pharmacol. Ther. 74, 437-447 (2003).
10. Chaobal, H.N. & Kharasch, E.D. Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam. Clin. Pharmacol. Ther. 78, 529-539 (2005).
11. Greenblatt, D.J., Abernethy, D.R., Locniskar, A., Harmatz, J.S., Limjuco, R.A. & Shader, R.I. Efect of age, gender, and obesity on midazolam kinetics. Anesthesiology 61, 27-35 (1984).
12. Klotz, U. & Ziegler, G. Physiologic and temporal variation in hepatic elimination of midazolam. Clin. Pharmacol. Ther. 32, 107-112 (1982).
13. Kharasch, E.D., Jubert, C., Senn, T., Bowdle, T.A. & Thummel, K.E. Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance. J. Clin. Pharmacol. 39, 664-669 (1999).
14. Bornemann, L.D. et al. Dose dependent pharmacokinetics of midazolam. Eur. J. Clin. Pharmacol. 29, 91-95 (1985).
15. Eap, C.B. et al. Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity. Eur. J. Clin. Pharmacol. 60, 237-246 (2004).
16. Croft, M., Keely, B., Morris, I., Tann, L. & Lappin, G. Predicting drug candidate victims of drug-drug interactions, using microdosing. Clin. Pharmacokinet. 51, 237-246 (2012).
17. Lappin, G. et al. Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. Clin. Pharmacol. Ther. 80, 203-215 (2006).
18. European Microdosing AMS Partnership Programme (EUMAPP) Funded by the European Commission under Framework Programme 6. Outcomes from EUMAPP-a study comparing in vitro, in silico, microdose and pharmacological dose pharmacokinetics. 〈http://www.eumapp.com/pdfs/EUMAPP%20SUMMARY.pdf〉.
19. Saleem, A., Aboagye, E.O., Matthews, J.C. & Price, P.M. Plasma pharmacokinetic evaluation of cytotoxic agents radiolabelled with positron emitting radioisotopes. Cancer Chemother. Pharmacol. 61, 865-873 (2008).
20. Vuongle, T. et al. Use of accelerator mass spectrometry to measure the pharmacokinetics and peripheral blood mononuclear cell concentrations of zidovudine. J. Pharm. Sci. 97, 2833-2843 (2008).
21. Madan, A. et al. A pharmacokinetic evaluation of fve H(1) antagonists after an oral and intravenous microdose to human subjects. Br. J. Clin. Pharmacol. 67, 288-298 (2009).
22. Yamazaki, A. et al. Microdose study of a P-glycoprotein substrate, fexofenadine, using a non-radioisotope-labelled drug and LC/MS/MS. J. Clin. Pharm. Ther. 35, 169-175 (2010).
23. Ieiri, I. et al. Microdosing clinical study: pharmacokinetic, pharmacogenomic (SLCO2B1), and interaction (grapefruit juice) profles of celiprolol following the oral microdose and therapeutic dose. J. Clin. Pharmacol. 52, 1078-1089 (2012).
24. Maeda, K. et al. Nonlinear pharmacokinetics of oral quinidine and verapamil in healthy subjects: a clinical microdosing study. Clin. Pharmacol. Ther. 90, 263-270 (2011).
25. Stoch, S.A. et al. Efect of diferent durations of ketoconazole dosing on the single-dose pharmacokinetics of midazolam: shortening the paradigm. J. Clin. Pharmacol. 49, 398-406 (2009).
26. Kusuhara, H. et al. Efects of a MATE protein inhibitor, pyrimethamine, on the renal elimination of metformin at oral microdose and at therapeutic dose in healthy subjects. Clin. Pharmacol. Ther. 89, 837-844 (2011).
27. Katzenmaier, S., Markert, C. & Mikus, G. Proposal of a new limited sampling strategy to predict CYP3A activity using a partial AUC of midazolam. Eur. J. Clin. Pharmacol. 66, 1137-1141 (2010).
28. Paine, M.F., Hart, H.L., Ludington, S.S., Haining, R.L., Rettie, A.E. & Zeldin, D.C. The human intestinal cytochrome P450 "pie". Drug Metab. Dispos. 34, 880-886 (2006).
29. Allonen, H., Ziegler, G. & Klotz, U. Midazolam kinetics. Clin. Pharmacol. Ther. 30, 653-661 (1981).
30. Tomalik-Scharte, D. et al. No role for the CYP3A5*3 polymorphism in intestinal and hepatic metabolism of midazolam. Eur. J. Clin. Pharmacol. 64, 1033-1035 (2008).
31. Miao, J. et al. Association of genotypes of the CYP3A cluster with midazolam disposition in vivo. Pharmacogenomics J. 9, 319-326 (2009).
32. Isoherranen, N. et al. The infuence of CYP3A5 expression on the extent of hepatic CYP3A inhibition is substrate-dependent: an in vitro-in vivo evaluation. Drug Metab. Dispos. 36, 146-154 (2008).
33. Shih, P.S. & Huang, J.D. Pharmacokinetics of midazolam and 1'-hydroxymidazolam in Chinese with diferent CYP3A5 genotypes. Drug Metab. Dispos. 30, 1491-1496 (2002).
34. Eap, C.B. et al. Pharmacokinetics of midazolam in CYP3A4-and CYP3A5-genotyped subjects. Eur. J. Clin. Pharmacol. 60, 231-236 (2004).
35. Yu, K.S. et al. Efect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. Clin. Pharmacol. Ther. 76, 104-112 (2004).
36. Kharasch, E.D. et al. Infuence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. Clin. Pharmacol. Ther. 82, 410-426 (2007).
37. Fredericks, S. et al. Genotyping cytochrome P450 3A5 using the Light Cycler. Ann. Clin. Biochem. 42, 376-381 (2005).